2024 ICD-10-CM Diagnosis Code C74.90

Approximate Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

• Abdominothoracic neuroblastoma
• Adrenal neuroblastoma
• Adrenal neuroblastoma
• International neuroblastoma pathology classification finding
• International neuroblastoma pathology classification finding
• International neuroblastoma pathology classification finding
• International neuroblastoma pathology classification finding
• International neuroblastoma pathology classification finding
• International neuroblastoma pathology classification finding
• International neuroblastoma pathology classification finding
• International neuroblastoma pathology classification finding
• International neuroblastoma pathology classification finding
• International neuroblastoma pathology classification: Favorable histology group, patient age 1.5 years up to but less than 5 years, with differentiating neuroblastoma , and low mitosis-karyorrhexis index
• International neuroblastoma pathology classification: Favorable histology group, patient less than 1.5 years of age, with poorly differentiated neuroblastoma , and low or intermediate mitosis-karyorrhexis index
• International neuroblastoma pathology classification: Favorable histology group, patient of any age with ganglioneuroblastoma, intermixed
• International neuroblastoma pathology classification: Favorable histology group, patient of any age with ganglioneuroma maturing, or mature
• International neuroblastoma pathology classification: Unfavorable histology group, patient 1.5 yr up to but less than 5 yr, with poorly differentiated neuroblastoma and any MKI or differentiating neuroblastoma and intermediate or high MKI
• International neuroblastoma pathology classification: Unfavorable histology group, patient 5 years or older, with any subtype of neuroblastoma and any mitosis-karyorrhexis index
• International neuroblastoma pathology classification: Unfavorable histology group, patient less than 1.5 years old, with poorly differentiated or differentiating neuroblastoma and high mitosis-karyorrhexis index
• International neuroblastoma pathology classification: Unfavorable histology group, patient of any age, with ganglioneuroblastoma, nodular
• International neuroblastoma pathology classification: Unfavorable histology group, patient of any age, with undifferentiated neuroblastoma and any mitosis-karyorrhexis index
• International neuroblastoma staging system stage 1
• International neuroblastoma staging system stage 2A
• International neuroblastoma staging system stage 2B
• International neuroblastoma staging system stage 3
• International neuroblastoma staging system stage 4
• International neuroblastoma staging system stage 4S
• International neuroblastoma staging system stage finding
• International neuroblastoma staging system stage finding
• International neuroblastoma staging system stage finding
• International neuroblastoma staging system stage finding
• International neuroblastoma staging system stage finding
• International neuroblastoma staging system stage finding
• Malignant tumor of adrenal gland
• Metastatic malignant neoplasm to adrenal gland
• Metastatic neuroblastoma
• Metastatic neuroblastoma
• Metastatic neuroblastoma
• Metastatic neuroblastoma
• Metastatic neuroblastoma
• Metastatic neuroblastoma
• Metastatic neuroblastoma
• Metastatic neuroblastoma to abdominothoracic structure
• Metastatic neuroblastoma to adrenal gland
• Metastatic neuroblastoma to brain
• Metastatic neuroblastoma to central nervous system
• Metastatic neuroblastoma to central nervous system
• Metastatic neuroblastoma to paraspinal area
• Metastatic neuroblastoma to pelvis
• Metastatic neuroblastoma to thorax
• Neuroblastoma
• Neuroblastoma of brain
• Neuroblastoma of central nervous system
• Neuroblastoma of central nervous system
• Pelvic neuroblastoma
• Primary adrenal neuroblastoma
• Primary hyperaldosteronism due to aldosterone-secreting malignant neoplasm of adrenal gland
• Primary malignant neoplasm of adrenal gland
• Thoracic neuroblastoma
• Thoracic neuroblastoma

Clinical Information

• Esthesioneuroblastoma, Olfactory

  a malignant olfactory neuroblastoma arising from the olfactory epithelium of the superior nasal cavity and cribriform plate. it is uncommon (3% of nasal tumors) and rarely is associated with the production of excess hormones (e.g., siadh, cushing syndrome). it has a high propensity for multiple local recurrences and bony metastases. (from holland et al., cancer medicine, 3rd ed, p1245; j laryngol otol 1998 jul;112(7):628-33)

• Neuroblastoma

  a common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. this tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (from devita et al., cancer: principles and practice of oncology, 5th ed, pp2099-2101; curr opin oncol 1998 jan;10(1):43-51)

• Retinoblastoma

  a malignant tumor arising from the nuclear layer of the retina that is the most common primary tumor of the eye in children. the tumor tends to occur in early childhood or infancy and may be present at birth. the majority are sporadic, but the condition may be transmitted as an autosomal dominant trait. histologic features include dense cellularity, small round polygonal cells, and areas of calcification and necrosis. an abnormal pupil reflex (leukokoria); nystagmus, pathologic; strabismus; and visual loss represent common clinical characteristics of this condition. (from devita et al., cancer: principles and practice of oncology, 5th ed, p2104)

• Metastatic Neuroblastoma

  a neuroblastoma that has metastasized from its original site of growth to another anatomic site.

C74.90 is grouped with Diagnostic Related Groups - MS-DRG Mapping

Diagnostic Related Groups (DRGs) are a classification system used to group together diagnosis codes for the purpose of reimbursement and healthcare management. DRGs are used to standardize the way hospitals and other providers are paid for inpatient services. In this system patients are grouped together based on their principal diagnosis in areas referred to as Major Diagnostic Categories (MDC). Once a patient is assigned a particular diagnostic category, providers receive a predetermined payment rate for the services rendered. This reimbursement rate is often fixed and is meant to cover the cost of care for that patient. Reimbursement is also affected by the relative weight of a diagnostic related group based on the severity of a patient's illness and the associated cost of care during hospitalization.

Diagnostic related groups encourage healthcare providers to focus on quality and efficiency in patient care while managing costs effectively. The diagnosis code is present in the following groups for version MS-DRG V41.0 applicable from 10/01/2023 through 09/30/2024.

MS-DRG	MS-DRG Title	MCD	Relative Weight
643	ENDOCRINE DISORDERS WITH MCC	10	1.6451
644	ENDOCRINE DISORDERS WITH CC	10	1.0617
645	ENDOCRINE DISORDERS WITHOUT CC/MCC	10	0.7609

The relative weight of a diagnostic related group determines the reimbursement rate based on the severity of a patient's illness and the associated cost of care during hospitalization.

Convert C74.90 to ICD-9-CM

• ICD-9-CM Code: 194.0 - Malign neopl adrenal
  Approximate Flag - The approximate mapping means there is not an exact match between the ICD-10 and ICD-9 codes and the mapped code is not a precise representation of the original code.

Table of Neoplasms

The parent code C74.9 of the current diagnosis code is referenced in the table of neoplasms by anatomical site. For each site there are six possible code numbers according to whether the neoplasm in question is malignant, benign, in situ, of uncertain behavior, or of unspecified nature. The description of the neoplasm will often indicate which of the six columns is appropriate.

Where such descriptors are not present, the remainder of the Index should be consulted where guidance is given to the appropriate column for each morphological (histological) variety listed. However, the guidance in the Index can be overridden if one of the descriptors mentioned above is present.

Filter table of neoplasms:

Neoplasm, neoplastic	Malignant Primary	Malignant Secondary	CaInSitu	Benign	Uncertain Behavior	Unspecified Behavior
»Neoplasm, neoplastic   »adrenal	C74.9	C79.7	D09.3	D35.0	D44.1	D49.7
»Neoplasm, neoplastic   »adrenal     »capsule	C74.9	C79.7	D09.3	D35.0	D44.1	D49.7
»Neoplasm, neoplastic   »adrenal     »gland	C74.9	C79.7	D09.3	D35.0	D44.1	D49.7
»Neoplasm, neoplastic   »suprarenal	C74.9	C79.7	D09.3	D35.0	D44.1	D49.7
»Neoplasm, neoplastic   »suprarenal     »capsule	C74.9	C79.7	D09.3	D35.0	D44.1	D49.7
»Neoplasm, neoplastic   »suprarenal     »gland	C74.9	C79.7	D09.3	D35.0	D44.1	D49.7

Patient Education

Adrenal Gland Cancer

Your adrenal, or suprarenal, glands are located on the top of each kidney. These glands produce hormones that you can't live without, including sex hormones and cortisol, which helps you respond to stress and has many other functions.

A number of disorders can affect the adrenal glands, including tumors. Tumors can be either benign or malignant. Benign tumors aren't cancer. Malignant ones are. Most adrenal gland tumors are benign. They usually do not cause symptoms and may not require treatment. Malignant adrenal gland cancers are uncommon.

Types of tumors include:

• Adrenocortical carcinoma - cancer in the outer part of the gland
• Neuroblastoma, a type of childhood cancer
• Pheochromocytoma - a rare tumor that is usually benign

Symptoms depend on the type of cancer you have. Treatments may include surgery, chemotherapy, or radiation therapy.

[Learn More in MedlinePlus]

Code History

• FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024
• FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
• FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
• FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
• FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
• FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
• FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
• FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
• FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016. This was the first year ICD-10-CM was implemented into the HIPAA code set.